Evidence map›Paper›PMID 41563825›Full record

ArticleJournal of the American Society of Nephrology : JASN2026

A Five-Plasma Protein-Based Algorithm for Predicting Incident CKD in Type 2 Diabetes.

Chenxin Xu, Chloe Yu-Yan Cheung, Junda Zhong, Yifen Lin, Carol Ho-Yi Fong, Xue Jiang, Xi Jia, David Tak-Wai Lui, Chi-Ho Lee, Karen Siu-Ling Lam and 1 more

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chenxin XuState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.ORCID 0000-0002-4138-3613
Chloe Yu-Yan CheungState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.
Junda ZhongState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.ORCID 0009-0003-7887-9166
Yifen LinState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.
Carol Ho-Yi FongState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.
Xue JiangState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.
Xi JiaState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.
David Tak-Wai LuiState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.ORCID 0000-0002-9813-1126
Chi-Ho LeeState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.ORCID 0000-0002-7569-409
Karen Siu-Ling LamState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.
Aimin XuState Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China.

Funding

Health and Medical Research Fund (HMRF) 06172266Hong Kong Research Grants Council/Area of Excellence AoE/M-707/18National Key R&D Program of China 2022YFA0806102National Natural Science Foundation of China (NSFC) grants 82070860National Natural Science Foundation of China (NSFC) grants 82161138026Shenzhen-Hong Kong-Macau Science and Technology Program SGDX20210823103537031
6 · The paper itself

Abstract

key pointsProteomics analyses consistently identified nine independent protein predictors for CKD in both Chinese and European participants with type 2 diabetes. A novel prediction model, "eGFR+five-protein panel predicting CKD," reliably predicted CKD with good performance (area under the receiver operating characteristic curve ≥0.80). The new "eGFR+five-protein panel predicting CKD" model exhibited superior performance over traditional clinical models.

backgroundCurrently, there is a lack of reliable biomarkers for noninvasive prediction of CKD in patients with diabetes. This study aimed to identify novel protein predictors and construct a prediction model for incident CKD in participants with type 2 diabetes applicable across different populations.

methodsA targeted Olink plasma proteomics profiling analysis, involving 368 proteins, was conducted in a nested case-control study comprising 132 incident CKD cases and 132 non-CKD controls, matched for age, sex, duration of diabetes, and eGFR, recruited from a long-term prospective cohort of Chinese type 2 diabetes participants (median approximately 9-year follow-up). False discovery rate was applied for multiple testing corrections. A q -value <0.2 was considered statistically significant. Three machine-learning approaches (Boruta, support vector machine, and eXtreme gradient boosting) were used for feature selection. Independent associations of proteins with incident CKD with adjustments for conventional clinical risk factors were examined in the training set ( n =1580, including 173 incident CKD cases and 1407 non-CKD controls; 70%) of the UK Biobank Pharma Proteomics Project (UKB-PPP) (median approximately 13.5-year follow-up). The least absolute shrinkage and selection operator-based Cox-regression analysis was used to develop the prediction model, which was subsequently validated in the testing set ( n =677, including 85 incident CKD cases and 592 non-CKD controls; 30%) of UKB-PPP.

resultsAmong the 18 identified protein features predictive of incident CKD, 12 showed significant associations with consistent direction of effects in both cohorts. A prediction model ("eGFR+five-protein panel predicting CKD [eGFR+FPPC]") combining eGFR and five proteins (α-1-microglobulin/bikunin precursor, matrix metallopeptidase 7, placental growth factor, TNF-related apoptosis-inducing ligand receptor 2, and kidney injury molecule-1) was constructed and validated in the testing and training sets of the UKB-PPP, respectively. The "eGFR+FPPC" model achieved superior predictive performance in both training (area under the receiver operating characteristic curve [95% confidence interval]: 0.82 [0.79 to 0.85]) and testing (area under the receiver operating characteristic curve [95% confidence interval]: 0.80 [0.74 to 0.86]) sets of UKB-PPP and yielded fewer indeterminate results compared with conventional clinical models.

conclusionsThe "eGFR+FPPC" model performed better than conventional clinical models in predicting incident CKD in type 2 diabetes participants across different populations.

Indexed as

AlgorithmsBlood ProteinsDiabetes Mellitus, Type 2Diabetic NephropathiesRenal Insufficiency, ChronicAgedBiomarkersCase-Control StudiesFemaleGlomerular Filtration RateHumansIncidenceMaleMiddle AgedPrediction AlgorithmsProspective StudiesBiomarkersBlood Proteinsbiomarkersdiabetic kidney disease

Identifiers

PMID41563825
PMCPMC13065152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.